Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Michael Kneidinger, MD, Peter Valent, MD, Karoline V. Gleixner, MD, Stefan Florian, MD, Alexandra Boehm, MD, Karoline Sonneck, MD, Margit Weghofer, Christian Lupinek, Susanne Vrtala, MD, Anja Vales, MD, Rudolf Valenta, MD, Giulio Superti-Furga, PhD, Francis Y. Lee, PhD

Blood (2006) 108 (11): 1365.

https://doi.org/10.1182/blood.V108.11.1365.1365

Published: 2006

Journal Articles

Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia.

Shaoguang Li, MD, PhD, Yiguo Hu, MD, Sarah Swerdlow, BS, Theodore M. Duffy, MS, Roberto Weinmann, PhD, Francis Y. Lee, PhD

Blood (2005) 106 (11): 1990.

https://doi.org/10.1182/blood.V106.11.1990.1990

Published: 2005

Journal Articles

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, M.Sc., Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, Roger Luo, PhD, David Kan, B.Sc, Veeraswamy Manne, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Roberto Weinmann, PhD, Robert Kramer, PhD

Blood (2005) 106 (11): 1993.

https://doi.org/10.1182/blood.V106.11.1993.1993

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Francis Y. Lee, PhD, Mei-Li Wen, M.Sc., Rajeev Bhide, PhD, Amy Camuso, B.Sc, Stephen Castenada, B.Sc, Krista Fager, B.Sc, Christine Flefleh, B.Sc, Ivan Inigo, B.Sc, David Kan, B.Sc, Roger Luo, PhD, Kelly McGlinchey, B.Sc, Richard Smykla, B.Sc, Robert Wild, PhD, Robert Borzilleri, PhD, Louis Lombardo, PhD

Blood (2005) 106 (11): 1994.

https://doi.org/10.1182/blood.V106.11.1994.1994

Published: 2005

Journal Articles

Targeting Chronic Myeloid Leukemia (CML) Stem Cells by BMS-214662 in Mice.

Cong Peng, MS, Yiguo Hu, MD, Francis Y. Lee, PhD, Shaoguang Li, MD, PhD

Blood (2005) 106 (11): 2861.

https://doi.org/10.1182/blood.V106.11.2861.2861

Published: 2005

Journal Articles

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Marcus M. Schittenhelm, MD, Sharon Shiraga, Arin Schroeder, Amie S. Corbin, Diana Griffith, Francis Y. Lee, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD, Michael C. Heinrich, MD

Blood (2005) 106 (11): 3358.

https://doi.org/10.1182/blood.V106.11.3358.3358

Published: 2005

Journal Articles

Simultaneous Targeting of SRC and BCR-ABL Kinases by BMS-354825 Cures Ph+ Acute Lymphoblastic Leukemia in Mice.

Shaoguang Li, MD, PhD, Yiguo Hu, BS, Sarah J. Swerdlow, BS, Francis Y. Lee, PhD

Blood (2004) 104 (11): 1976.

https://doi.org/10.1182/blood.V104.11.1976.1976

Published: 2004

Journal Articles

Comparative Analysis of Two BCR-ABL Small Molecule Inhibitors Reveals Overlapping but Distinct Mechanisms of Resistance.

Michael R. Burgess, Neil P. Shah, MD, PhD, Brian J. Skaggs, PhD, Francis Y. Lee, PhD, Charles L. Sawyers, MD

Blood (2004) 104 (11): 552.

https://doi.org/10.1182/blood.V104.11.552.552

Published: 2004

Journal Articles

BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant.

Neil P. Shah, MD, PhD, Francis Y. Lee, PhD, Charles L. Sawyers, MD, Cem Akin, MD, PhD

Blood (2004) 104 (11): 797.

https://doi.org/10.1182/blood.V104.11.797.797

Published: 2004

Journal Articles

The Dual SRC/ABL Kinase Inhibitor BMS-354825 Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by FLT3-ITD Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an ABL-Independent Mechanism.

Jukka Kanerva, MD, PhD, Ogonna Nwawka, BS, Kevin Hwang, Francis Y. Lee, PhD, Seth J. Corey, MD, MPH

Blood (2004) 104 (11): 4480.

https://doi.org/10.1182/blood.V104.11.4480.4480

Published: 2004

NARROW

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia.

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).

Targeting Chronic Myeloid Leukemia (CML) Stem Cells by BMS-214662 in Mice.

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Simultaneous Targeting of SRC and BCR-ABL Kinases by BMS-354825 Cures Ph+ Acute Lymphoblastic Leukemia in Mice.

Comparative Analysis of Two BCR-ABL Small Molecule Inhibitors Reveals Overlapping but Distinct Mechanisms of Resistance.

BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant.

The Dual SRC/ABL Kinase Inhibitor BMS-354825 Potently Inhibits the Growth of Myeloid Leukemic Cells Characterized by FLT3-ITD Expression, GM-CSF Dependency, or G-CSF Responsiveness Via an ABL-Independent Mechanism.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only